# A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta

> **NCT01650779** · PHASE4 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 15 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** Agalsidase beta

## Key facts

- **NCT ID:** NCT01650779
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2014-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01650779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01650779, "A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01650779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*